Amgen’s two osteoporosis treatments, Prolia (denosumab) and Evenity (romosozumab) are repeatedly posting high growth in sales. Together, these two treatments generated over 130 billion won in Q3 sales, dominating the osteoporosis treatment market in Korea.

In the first-line, osteoporosis treatment is trending towards sequential Evenity followed by Prolia for high-risk fracture osteoporosis patients. With this approach increasingly becoming the norm, the analysis is that these two treatments are deemed to be making a synergistic effect, leading to improved outcomes.

Prolia's Q3 cumulative sales up 33% YoY…over 150 bil won expected by the end of the year

Acc